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Y5 receptorNeuropeptide Y (NPY) inhibits TRH neurons in fed state, and hypothalamic NPY higher expression during
fasting has been proposed to be involved in fasting-induced suppression of the hypothalamus-pituitary–
thyroid (HPT) axis. We investigated the role of central Y5 receptors in the control of thyrotropin (TSH) and
thyroid hormone (TH) secretion. Fed and fasting rats received twice daily central injections (3rd ventricle) of
Y5 receptor antagonist (CGP71683; 15 nmol/rat) for 72 h. Fasted rats also received a single central injection of
CGP71683 (15 nmol/rat) at the end of 72 h of fasting. In fed rats, Y5 receptor blockade reduced total food
intake by 32% and body mass by almost 10% (pb0.01), corroborating the role of this receptor in food intake
control. 72 h-fasted rats exhibited a 4-fold increase in serum TSH (pb0.001), 1 h after a single injection of Y5
antagonist. Also with multiple injections during 72 h of fasting, Y5 blockade resulted in activation of thyroid
axis, as demonstrated by a 3-times rise in serum T4 (pb0.001), accompanied by unchanged TSH and T3. In fed
rats, the chronic central administration of CGP71683 resulted in reduced total serum T4 without changes in
free T4 and TSH. Serum leptin and PYY were not altered by the NPY central blockade in both fed and fasted
rats, suggesting no role of these hormones in the alterations observed. Therefore, the inhibition of central Y5
neurotransmission resulted in activation of thyroid axis during fasting suggesting that NPY-Y5 receptors
contribute to fasting-induced TSH and TH suppression.o Rio de Janeiro, Instituto de
e, Avenida Carlos Chagas Filho,
e Janeiro, RJ, 21941-902, Brazil.
ura).
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Fasting-induced hypothalamus-pituitary–thyroid (HPT) axis sup-
pression is believed to represent an adaptive response to energy
deprivation [1–3]. In rodents, prolonged fasting results in decreased
preproTRH expression in neurons of hypothalamic paraventricular
nucleus (PVN) accompanied by low or inappropriately normal serum
thyrotropin (TSH) and reduction of serum thyroid hormone concen-
trations [4,5]. Peripheral metabolic signals may play a role in this
phenomenon, but the precise related mechanisms remain unknown.
Since circulating levels of leptin are reduced in fasted animals and
its administration increases both preproTRH expression and serum
TSH, it has been proposed a role for this hormone in the control of HPT
axis activity [6–8]. Effects of leptin on TRH neurons of the PVN may
be direct and indirect. The indirect pathway is related to increasedCREB phosphorylation and may result from the action of leptin on
hypothalamic arcuate nucleus (ARC) [9], where leptin has the ability
to revert the fasting-induced changes in expression of many genes,
including NPY, which expression is increased during fasting [10,11].
It has been demonstrated that NPY neurons innervate hypophysio-
tropic TRH neurons of the PVN [12] and that ARC is a major source of
these NPY neurons projecting to TRH neurons [13]. In addition, NPY-
containing axon terminals of medulla origin innervate TRH neurons in
the PVN. These medulla NPY neurons co-localize with cathecholamine
[12,14,15] and, therefore NPY is co-released with cathecolamines and
may potentially modulate their actions on hypophysiotropic TRH
neurons. Previous reports have shown that central NPY administration
promotes suppression of HPT axis in fed rats [16,17], and that central
administration of either Y1 or Y5 receptors agonists reduced proTRH
mRNA expression in the PVN of fed rats, as well as their thyroid
hormone serum levels in the presence of low or inappropriately normal
TSH [18]. Thus, increased Y receptors activation and, consequently,
inhibition of the cAMP-CREB signalling pathway, may contribute to
suppressed preproTRH expression that occurs during fasting. Therefore,
as proposed before [16–18], increased NPY neurotransmission to TRH
neurons could play amajor role in fasting-inducedHPT axis suppression
[16], an effect possibly mediated by Y1 and Y5 receptor activation.
44 R.H. Costa-e-Sousa et al. / Regulatory Peptides 171 (2011) 43–47In the present study we addressed the question of the role of NPY
action through Y5 receptors in the control of pituitary–thyroid axis
during fasting, employing a pharmacological central blockade approach.
Although Y1 blockade was also performed, most of the animals
exhibited the barrel rolling behaviour and thus, the results were not
reliable. Therefore, here we report the effects of the central Y5 blockade
on thyrotropin and thyroid hormones secretion of animals in fed and
fasted state.
2. Materials and methods
2.1. Animals
Experiments were performed on 3 months old male Wistar rats,
kept in individual cages under a 12:12 h light/dark cycle (lights on at
7:00) at 23–25 °C. All protocols were approved by the Institutional
Animal Care and Use Committee of Biophysics Institute Carlos Chagas
Filho.
2.2. Stereotaxic surgery
Rats underwent third ventricular cannulation (i.c.v.) 7 to 10 days
prior to the experiment. Brieﬂy, a stainless steel guide cannula (0.6 mm
o.d.; Acerionx, São Paulo, Brazil) for microinjection was implanted
0.5 mm posterior to bregma and 8.0–8.5 mm ventral to skull [19–21],
under ketamine+xylazine anesthesia. Veriﬁcation of correct cannula
placementwasmadeby theobservationofﬂuid-ﬁlled column(attached
to guide cannula) displacement, as described before [21,22].
2.3. Protocols
The Y5 receptor antagonist, CGP71683 (Tocris, MO, USA), was
dissolved in 30%DMSO and kept frozen at−20 °C until the experiment.
Each microinjection consisted of 2 μL of either vehicle (30% DMSO) or
CGP71683 (7.5 nmol/μL; 15 nmol/rat) [23] injected during 30–60 s
through the guide cannula, as the following protocols: I – rats with free
access to chow received 6 microinjections (15 nmol/rat, 10–14 h
interval between each one) and were killed 1 h after the last injection,
between 9 and 10 a.m. Food intake was estimated by the reduction in
chow mass (g), evaluated daily, immediately before each icv injection.
II – 72 h-fasted rats received a single microinjection of vehicle or
CGP71683 (15 nmol/rat) and sacriﬁced 1 h latter. III – during a period of
72 h of fasting, rats were treated with multiple injections of vehicle or
CGP71683 with the same protocol used for fed animals, and the fasting
period started 10 h before the ﬁrst microinjection. At the end of
experimental protocols, rats were decapitated and serumwas obtained
from trunk blood for the measurement of the concentrations of
hormones.
2.4. Hormone measurements
Serum TSH concentrations were measured by speciﬁc RIA, employ-
ing reagents supplied by National Hormone and Peptide Program
(Torrance, CA,USA)aspreviouslydescribed [24], and itwasexpressed in
terms of the reference preparation 3 (RP3). Minimum assay detection
value was 0.18 ng/ml and intra-assay variation coefﬁcient was less than
8% in all assays. Free serum T4, total serumT4 and T3weremeasured by
RIA commercial kits (Mab-ICN Pharmaceuticals, Costa Mesa, CA, USA).
Minimum assay detection value was 0.15 ng/dL for free T4, 25 ng/dl for
total T3 and 1 μg/dl for total T4. The intra-assay variations were 1.2%,
1.8% and 3.7%, respectively. Samples of the same experiment were
measured within the same assay.
Serum leptin and PYY were determined by speciﬁc rodents
radioimmunoassay kits (Linco Research, MA, USA) in accordance
with the recommendations of manufacturers. Theminimum detection
value was 0.5 ng/mL and 15.6 pg/mL for leptin (4.6% of intra-assayvariation) and PYY (1.8% of intra-assay variation), respectively. All
samples to be compared were measured within the same assay.
2.5. Statistics
Data are reported as means±S.E.M. Serum TSH was analyzed
employing Mann–Whitney test and for temporal food intake analysis
we employed two-way ANOVA, followed by Bonferroni post test. All
other results were analyzed by unpaired t test. Null hypothesis was
discarded when pb0.05.
3. Results
3.1. Central Y5 receptors blockade and food consumption and body
weight of fed animals
Previous studies have shown that CGP71683, a Y5 receptor
inhibitor, has the ability to reduce food intake, and in order to test
the effectiveness of the present treatment protocol with the Y5
antagonist, CGP71683, we tested food ingestion and body weight.
Twice daily intracerebroventricular (icv) injections of the Y5 receptor
antagonist, CGP71683, for 72 h reduced total food intake by 32%
(p=0.014 – Fig. 1B). The anorexigenic effect of CGP71683 was more
evident during the dark phase after the ﬁrst injection (Fig. 1A), when
food ingestion was reduced by almost 50% (pb0.01). In addition, at
the end of the treatment the CGP71683-treated rats had lost almost
10% of total body mass (pb0.001 – Fig. 1C).
3.2. Central Y5 blockade and thyroid axis function of fasted animals
3.2.1. Single icv administration
Rats treated with a single icv dose of CGP71683 after being fasted
for 72 h, and sacriﬁced 1 h later, showed a 4-times increase in serum
TSH concentration (pb0.001), without signiﬁcant change in total or
free T4 and in total T3 concentration as compared to fasted controls
(p=0.195, p=0.4 and p=0.085 – Fig. 2).
3.2.2. Multiple icv administration
Twice daily icv administration of CGP71683 for 72 h resulted in
3-times higher serum total T4 and 37% increase in free T4 in the fasted
group treated with CGP71683 than in fasting controls treated with
vehicle (pb0.001). Serum TSH and T3 concentrations remained
statistically undistinguished between groups (Fig. 2). Body mass loss
was also higher in CGP71683-treated group (17.32±0.38 vs. 15.29±
0.43%, CGP71683 vs. vehicle respectively; p=0.002). CGP71683
treatment did not change either PYY or leptin concentration of fasted
rats (Table 1).
3.3. Central Y5 blockade and thyroid axis function of fed animals
We also tested the effect of multiple icv injections on central Y5
blockade on pituitary thyroid axis of fed rats (Fig. 3). Total serum T4
was reduced by 62% as compared to control levels, but not free serum
T4 that was similar between groups. Total T3 was slightly reduced by
18% (p=0.033). There was no signiﬁcant difference in serum TSH
(p=0.34). Circulating leptin and PYY did not differ signiﬁcantly
between groups (Table 1).
4. Discussion
The present study demonstrates for the ﬁrst time that the
pharmacological blockade of Y5 receptors results in activation of the
pituitary–thyroid axis during fasting. This ﬁnding strongly supports
the previous concept that the higher NPY expression is a physiological
phenomenon that contributes importantly to the axis suppression
during fasting [16–18,25].
Fig. 1. Effect of multiple central (3rd ventricle) administration of Y5 antagonist (CGP71683; 15 nmol/rat, twice daily, during 72 h) on fed rats. (A) Food intake: arrows indicate the
time of microinjection and black/white bars correspond to dark/light periods respectively. **pb0.01; (B) Cumulative food intake; (C) Change in total body mass relative to pre-
injection. Data are presented as mean±S.E.M. n=10 rats per group.
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observed during fasting result, mainly, from the suppression of the
stimulatory action of the hypothalamus-pituitary axis on thyroidFig. 2. Effect of a single (ﬁrst column) andmultiple (second column) central (3rd ventricle) a
sacriﬁce or multiple administration twice daily during 72 h) on serum TSH, total and free T4function [1–5,26]. Based on previous studies showing that an Y5 agonist
was able to suppress preproTRH expression [15] in fed rats, central Y5
receptor blockade would increase TRH synthesis and release, resultingdministration of Y5 antagonist (CGP71683; 15 mol/rat, single administration 1 h before
and total T3 of fasted rats. Data are presented as mean±S.E.M n=10–11 rats per group.
Table 1
Serum leptin and PYY of fed and fasted animals after multiple intracerebroventricular
injections of NPY-Y5 antagonist (CGP71683).
Group Leptin (ng/mL) P PYY (pg/mL) P
Fed Control 3.09±0.35 0.95 110.7±9.6 0.94
CGP 3.13±0.48 109.6±10.8
Fasted Control 1.10±0.19 0.54 106.9±12.2 0.53
CGP 1.39±0.41 118.7±13.9
n=10–11animals/group.
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This is in agreement with our acute experiment, when a single
intracerebroventricular dose of the Y5 antagonist (CGP71683) resulted
in a rapid increase in serum TSH of fasted animals. In addition, the
chronic blockade of central Y5 receptors during fasting also activated
the thyroid axis, as indicated by the higher serum total and free T4 of the
animals treatedwith the antagonist during 03 days. In those rats, serum
TSH had returned to similar levels of the fasting controls, probably
due to the feedback of T4, counteracting the stimulatory effect of TRH
on TSH release. However, the higher serum T4 in the presence of the
same level of TSH of fasting controls also suggests that TSH of the
antagonist-treated group presented a higher biological activity. This
argues in favour of the hypothesis of an increased TRH production since
an important action of TRH is to increase TSH biological activity, by
regulation of the appropriate glycosylation of the hormone [27].
Even though fasting Y5 antagonist-treated rats exhibited increased
serumT4, their serumT3remained statistically similar to controls. These
data raise the possibility that the Y5 antagonist caused a decrease in the
conversion of T4 to T3, catalyzed by 5′ deiodinases. The possibility that
Y5 receptors are involved in the regulation of 5´dediodinase activitywas
suggested before in a previous study showing that an Y5 agonist,
administered centrally to rats, was able to increase the 5´dediodinase
activity of brown adipose tissue [18]. However, more speciﬁc studies
will have to address this question.
Interestingly, CGP71683-treated fasted rats lost more weight than
vehicle-treated fasted rats, supporting an involvement of Y5 receptors
in energy expenditure independent of food consumption. Other
studies have proposed that NPY via Y5 receptors decreases energy
expenditure by affecting thermogenesis in brown and white adipose
tissue [28,29].
Present data also support an important role for Y5 receptors in the
control of food intake, as previously described byothers [28–30]. In free-
fed rats, the icv administration of the Y5 receptor antagonist induced a
reduction in total food intake during the 72 h of the treatment, without
modifying light phase food intake and with a marked effect during the
dark phase after the ﬁrst injection, corroborating previous studies [30].
The decrease in food intake is themajor determinant of the bodyweight
lost. These animals exhibited serum TSH that did not differ fromFig. 3. Effect of multiple central (3rd ventricle) administration of Y5 antagonist (CGP71683; 1
rats. Data are presented as mean±S.E.M n=10 rats per group.controls, reduced total serum T4, but normal free T4, This suggests a
reduction in the serum thyroid binding proteins, which is known to
occur in nutritional deprivation [31], and thus, may be correlated to the
body weight reduction caused by chronic central CGP treatment.
Nevertheless, it is clear that a persistent stimulation of pituitary–thyroid
axis by chronic Y5 blockade occurs only during fasting. This may be
related to thehigherNPY input to TRHneurons that is possibly occurring
in the fasting state [10,11].
Leptin stimulates the HPT axis, acting directly and indirectly at TRH
neurons [9] and PYY3-36 has been shown to be able to acutely stimulate
TSH secretion in fasted rats [32]. However, the effects of central Y5
blockade on the pituitary–thyroid axis observed in the present study
were independent of changes in serum leptin or PYY, both in fed and
fasted states. This reinforces the conclusion that the effects observed
were the result of Y5 receptors blockade directly at the central nervous
system.However, theprecisemechanisms involved in the stimulationof
pituitary–thyroid axis by Y5 central blockade in fasting are still unclear.
In addition to a possible direct antagonism of Y5 receptors in TRH
neurons, another important potential mechanism is a blockade of the
inhibitory effects ofNPYon themelanocortin system,which inactivation
during fasting contributes to the decrease in TRH synthesis [33]. It also
should be considered that, even though not predominant, NPY
innervation to TRH neurons also arises from cathecolaminergic neurons
in the medullae. Thus, NPY-Y5 receptor antagonism may also reﬂect
consequences of the action of NPY as a sympathetic co-transmitter that
potentially could modulate the inﬂuence of adrenergic ﬁbers on TRH
neurons [12,14,15].
Previous study [18] had demonstrated the involvement of Y1
receptors in the inhibitionofHPTaxis exertedbyNPYneurotransmission.
As mentioned before, we have tested an Y1 receptor antagonist
(BIBP3226), however the results were inconclusive because the drug
induced the barrel rolling behaviour in most of the animals. The same
behaviour was observed by others using either a different Y1 antagonist
[34] or anantibody againstNPYmicroinjected into ventrolateral thalamic
area [35].
In conclusion, blockade of Y5 receptors within the central nervous
system of fasted rats stimulated the pituitary–thyroid axis, suggesting
that increased NPY neurotransmission, via Y5 receptors activation, is
an important energy sparing response activated during prolonged
fasting.Acknowledgments
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